ASCO 2017 Prostate Cancer

Viewing 1-20 of 85 articles

ASCO 2017: Does Prostate Cancer Presentation and Biologic Characteristics Differ in Older Patients?

ASCO 2017: How Randomized Trials of STAMPEDE Have Influenced Treatment Decisions in the United Kingdom

ASCO 2017: Physical and Cognitive Effects of Systemic Therapy in Older Men with Prostate Cancer

ASCO 2017: Key Interdisciplinary and Integrated Treatment Planning Necessary to Effectively Treat Older Adults With Prostate Cancer

ASCO 2017: How Advances in Molecular Imaging Have Changed Our Understanding of State and Stage of the Disease

ASCO 2017: Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP)

ASCO 2017: Targeting the AR: Biomarkers and Novel Therapeutic Approaches

ASCO 2017: Have Decisions by the National Institute for Health and Care Excellence Affected Outcomes of British Patients With Metastatic Castration-Resistant Prostate Cancer?

ASCO 2017: Intensification of Therapy for Locally Advanced and Oligometastatic Disease (Discussing Abstract 5018, 5019, 5020)

ASCO 2017: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer

ASCO 2017: PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration

ASCO 2017: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer

ASCO 2017: Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis

ASCO 2017: Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial

ASCO 2017: Prostate cancer in 696 hypogonadal men with and without long-term testosterone therapy: Results from a controlled registry study

ASCO 2017: Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer

ASCO 2017: A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC)

ASCO 2017: Avelumab in metastatic castration-resistant prostate cancer (mCRPC)

ASCO 2017: Assessment of quality of life, cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC)

ASCO 2017: Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer

1
2
3
4
5

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.